Navigation Links
Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection

Study Shows Safety and Pharmacokinetics Similar to IV Doses in Phase 3 CLL Trial

BERKELEY HEIGHTS, N.J., June 06, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the publication of preliminary clinical results that show the Company's lead anti-cancer drug, Genasense(R) (oblimersen sodium) injection, can be safely administered by intermittent subcutaneous (SC) injection, as well as by brief intravenous (IV) infusion. These regimens may eventually reduce or eliminate the current requirements for administering Genasense by continuous IV (CIV) infusion. The new schedules also expand the potential for use in combination with anticancer drugs that are administered on a daily or weekly basis. The data were published in proceedings of the annual meeting of the American Society of Clinical Oncology (ASCO) that was held this week in Chicago, IL.

The SC study used a new formulation of Genasense that was concentrated 5- fold greater than that used in previous Phase 3 trials. In a dose-ranging pharmacokinetic (PK) and pharmacodynamic trial, bolus SC injections of 75, 150 and 225 mg yielded dose-proportional plasma concentrations that were associated with down-regulation of Bcl-2 in blood cells. The 225 mg dose level achieved exposure PK parameters that were similar to levels achieved at the 3 mg/kg CIV daily dose level that was tested in the recent Phase 3 trial of Genasense in chronic lymphocytic leukemia (CLL).

A second phase of the program is testing escalating doses of Genasense administered as a 2-hour IV infusion. Single 150 mg doses, as well as repeated 150 mg doses administered daily for 5 consecutive days, have been well-tolerated. To date, the principal adverse events have been reversible skin reactions at the injection site on the SC schedule and transient fever on the brief IV schedule.

"These highly encouraging data represent important next steps that may greatly improve dosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... MOUNTAIN VIEW, Calif., Nov. 11 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Lazard Capital Markets 6th Annual Healthcare Conference on ... York City. , A live webcast of the presentation ... Pharmaceuticals, website at http://www.mappharma.com . A replay will also ...
... Finland, November 11 , ... be issued by the Finnish,Breast Cancer Group on Wednesday 11 November ... III Randomised Study in Women With Early Breast,Cancer Shows that Adding ... to Live Cancer-Free for Longer , An ...
Cached Medicine Technology:Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 2Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... May 2008] Golf can be a good investment for the ... university Karolinska Institutet. The death rate for golfers is 40 ... sex, age and socioeconomic status, which correspond to a 5 ... are the safest. , It is a well-known fact ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... PRINCETON JUNCTION, N.J., May 30 Lutronic, Inc., ... medical laser systems,announced today that its MOSAIC eCO2 ... fractional technology with the deep,ablative features of a ... FDA review and,clearance., With intuitive touch-screen software, ...
... options, TORONTO, May 30 /PRNewswire-FirstCall/ - Predictive ... announced it has been notified by,the American Stock ... to,support PreMD,s plan for regaining compliance with the ... the Company,s common stock from the,Exchange by filing ...
... than white women to receive the radiation therapy routinely ... a study that Dana-Farber Cancer Institute researchers will present ... Clinical Oncology in Chicago. , Although the disparity in ... of black and Hispanic breast cancer patients may be ...
... Medical researchers at The Ohio State University, in ... million grant from the National Institutes of Health to ... that help identify and advance treatments for patients. The ... Ohio State. , The Ohio State University Center for ...
Cached Medicine News:Health News:Golf prolongs life 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: